La vendita allo scoperto per Streamline Health Solns dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Streamline Health Solns. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Streamline Health Solns (NASDAQ:STRM) Azioni, Report sulle vendite allo scoperto

Streamline Health Solns

Streamline Health Solutions Inc provides transformational data-driven solutions for healthcare organizations. It provides computer software-based solutions through its looking glass platform. Its solutions include coding and CDI, coding audit, and financial management solutions. It offers various services, such as custom integration services, training services, electronic image conversion and database monitoring services. It sells its solutions and services in North America to hospitals and health systems, including physician practices, through its direct sales force and its reseller partnerships.

Streamline Health Solutions, Inc. - Common Stock

Streamline Health Solutions Inc

WIIM

STRM

Streamline Health Solutions shares are trading higher after the company announced it signed a new contract.

News

Contracts

Streamline Health Signs New Contract For Use Of eValuator With 900-Bed, Altera EHR-Based Health System Serving Northern Texas

Streamline Health Solutions Announced That It Has Expanded Its Relationship With An Existing eValuator Client Include The Recently Released eValuator Quality Module

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 55.3% to $1.91 during Wednesday's regular session. The company's market cap stands at $3.5 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) stock rose 24.54% to $2.74. The company's market cap stands at $11.5 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) shares moved upwards by 22.68% to $1.46. The market value of their outstanding shares is at $10.8 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) stock moved upwards by 18.28% to $0.88. The company's market cap stands at $63.8 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) shares rose 15.88% to $1.46. The company's market cap stands at $69.6 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock moved upwards by 15.78% to $6.6. The market value of their outstanding shares is at $102.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 22.0% to $0.72 during Wednesday's regular session. The company's market cap stands at $1.1 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares declined by 21.52% to $2.17. The company's market cap stands at $6.9 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock fell 16.32% to $1.21. The market value of their outstanding shares is at $47.6 million. </li>
<li>Regional Health Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RHE#AMEX">RHE</a>) stock decreased by 14.09% to $2.13. The market value of their outstanding shares is at $4.0 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 13.64% to $0.23. The company's market cap stands at $1.3 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 11.72% to $0.1. The company's market cap stands at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEON

CASI

NUWE

OTRK

STTK

TIVC

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares rose 77.0% to $5.94 during Friday's pre-market session. The company's market cap stands at $4.4 million. </li>
<li>Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) stock moved upwards by 28.6% to $52.98. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock rose 17.89% to $0.29. The market value of their outstanding shares is at $7.0 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock rose 10.25% to $0.86. The market value of their outstanding shares is at $161.5 million. </li>
<li>Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock increased by 9.77% to $11.75. The market value of their outstanding shares is at $1.8 billion. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 9.56% to $0.3. The market value of their outstanding shares is at $2.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares fell 18.6% to $1.66 during Friday's pre-market session. The company's market cap stands at $2.2 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) shares decreased by 17.12% to $3.73. The market value of their outstanding shares is at $49.7 million. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock fell 16.11% to $2.39. The company's market cap stands at $14.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares declined by 14.29% to $3.42. The market value of their outstanding shares is at $6.0 million. </li>
<li>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) shares declined by 10.53% to $28.51. The company's market cap stands at $1.3 billion. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares fell 10.35% to $0.21. The market value of their outstanding shares is at $13.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AYTU

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CERT

ENSC

ESTA

NVNO

ONCO

SAVA

TBIO

TOVX

12 Health Care Stocks Moving In Friday's Pre-Market Session

The 1-for-15 ratio is within the range approved by the Company&#39;s stockholders at the Special Meeting of Stockholders held on September 19, 2024.

Stock Split

Streamline Health Plans To Proceed With 1-For-15 Reverse Stock Split Of Its Outstanding Shares Of Common Stock

<h3>Gainers</h3>
<ul>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock increased by 16.8% to $0.29 during Thursday's after-market session. The company's market cap stands at $6.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock rose 6.69% to $6.16. The market value of their outstanding shares is at $3.1 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) shares moved upwards by 6.01% to $0.88. The company's market cap stands at $134.0 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 5.88% to $1.08. The company's market cap stands at $6.2 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 5.4% to $1.17. The company's market cap stands at $7.1 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 5.2% to $0.26. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares decreased by 27.8% to $0.33 during Thursday's after-market session. The company's market cap stands at $15.9 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock declined by 15.34% to $3.81. The market value of their outstanding shares is at $50.7 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock decreased by 7.04% to $3.7. The market value of their outstanding shares is at $6.5 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares declined by 6.17% to $0.21. The company's market cap stands at $13.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock fell 5.38% to $0.48. The market value of their outstanding shares is at $3.8 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) shares declined by 5.12% to $14.27. The market value of their outstanding shares is at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIVI

CHRO

CPHI

LIPO

MCRB

TCBP

TVTX

12 Health Care Stocks Moving In Thursday's After-Market Session

Streamline Health Solutions shares are trading lower after the ocmpany reported mixed Q2 financial results.

The Company reiterated that it believes its adjusted EBITDA breakeven run rate is&nbsp;$15.5 million&nbsp;of implemented SaaS ARR, but due to the aforementioned client non-renewals, the Company has revised its expected timeline to achieve this run rate from the second half of fiscal 2024 to the second half of fiscal 2025.

Guidance

Streamline Health Revises Expected Timeline To Achieve SaaS ARR Adjusted EBITDA Breakeven Run Rate From H2 Of FY24 To H2 Of FY25

Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 25 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $4.48 million which beat the analyst consensus estimate of $4.33 million by 3.25 percent. This is a 22.43 percent decrease over sales of $5.77 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Streamline Health Solns Q2 2024 GAAP EPS $(0.05) Misses $(0.04) Estimate, Sales $4.48M Beat $4.33M Estimate

Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-09-11. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Streamline Health Solns will report an earnings per share (EPS) of $-0.04.
Streamline Health Solns bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.01, leading to a 19.53% drop in the share price the following trading session.
Here's a look at Streamline Health Solns's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.04</td>
<td>-0.04</td>
<td>-0.04</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-20.0%</td>
<td>-4.0%</td>
<td>7.000000000000001%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1725979881_0.png" alt="eps graph" />
<h3>Market Performance of Streamline Health Solns's Stock</h3>
Shares of Streamline Health Solns were trading at $0.4577 as of September 09. Over the last 52-week period, shares are down 52.18%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/STRM/earnings">To track all earnings releases for Streamline Health Solns visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Streamline Health Solns's Earnings Outlook

Streamline Health shares are trading higher after the company announced a new eValuator contract with 750-bed Academic Medical Center.

General

Streamline Health Bags New eValuator Contract With 750-Bed Academic Medical Center In Texas

Shares of Streamline Health Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) fell sharply during Wednesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/STRM/earnings">first-quarter EPS results</a>.
Streamline Health reported quarterly losses of 5 cents per share which missed the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $4.33 million which beat the analyst consensus estimate of $4.31 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Streamline Health Solutions shares dipped 23.3% to $0.4902 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) surged 101% to $1.04. DDC Enterprise said it has acquired Omsom.</li>
<li>Golden Heaven Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares climbed 59.7% to $0.2866.</li>
<li>Beamr Imaging Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMR#NASDAQ">BMR</a>) gained 39.3% to $6.08 after the company announced that its Beamr Cloud solution has achieved Powered by Expertise and is now available in the Oracle Cloud Marketplace.</li>
<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) climbed 27% to $36.56 after the company announced initial AOC 1020 data from the Phase 1/2 FORTITUDE trial demonstrating reductions of greater than 50% in DUX4 regulated genes, trends of functional improvement, and favorable safety and tolerability in people living with facioscapulohumeral muscular dystrophy.</li>
<li>Direct Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) jumped 26.6% to $3.99.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares rose 24.3% to $0.7602 after surging 16% on Tuesday.</li>
<li>MediaCo Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) rose 20.5% to $1.92. BestGrowthStocks.com issued comprehensive evaluation of MediaCo Holding Inc.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) gained 18.6% to $7.41.</li>
<li>Casey&#8217;s General Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) rose 16.5% to $380.41 after the company reported better-than-expected quarterly financial results. Also, the company increased its quarterly dividend.</li>
<li>Hudson Pacific Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) surged 15.8% to $5.41.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) jumped 15.6% to $6.15.</li>
<li>Rentokil Initial plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>) gained 15.5% to $31.10 following a report suggesting Trian has amassed a stake in the company.</li>
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) rose 15.5% to $4.0650 after the company and Ultragenyx Pharmaceutical announced 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study.</li>
<li>Fenbo Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) climbed 15.4% to $14.88.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) gained 13.8% to $38.45. Brittain Resorts &amp; Hotels selected Affirm as exclusive pay over time partner to bring hotel guests a more flexible way to book accommodations.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 13% to $3.92.</li>
<li>Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) gained 12.8% to $47.12. Zillow Group Director Jay C Hoag acquired a total of 2,338,036 shares at an average price of $42.76.</li>
<li>Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) gained 10.7% to $137.08 after the company reported fourth-quarter financial results. Oracle posted weaker-than-expected earnings for its fiscal fourth quarter. The company also announced a partnership with Alphabet Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google Cloud.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) climbed 10.3% to $26.83.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) rose 9.9% to $13.58.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) gained 3.7% to $214.73.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares dipped 46.2% to $1.1469. Tonix Pharmaceuticals priced its $4 million public offering of 3,753,558 shares of common stock at $1.065 per share.</li>
<li>ZKH Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) fell 35.7% to $8.69.</li>
<li>ThermoGenesis Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) fell 31% to $0.3780 after the Nasdaq denied the company's request for continued listing and the stock will be suspended at the opening of business on June 17.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) tumbled 31% to $0.1870. The company recently announced that it may now offer and sell shares of common stock offering price of up to $8.4 million from time to time through or to Wainwright.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) fell 24.1% to $0.82.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) shares fell 20.1% to $0.8168 after jumping around 17% on Tuesday. KWESST Micro Systems was recently awarded a sub-contract worth up to C$48 million by Thales Canada for software development services.</li>
<li>Vera Bradley, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) declined 16.8% to $6.44 following a first-quarter revenue miss and weak FY25 guidance.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) fell 15.8% to $1.6150.</li>
<li>Calidi Biotherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) shares fell 14.1% to $4.1350 after jumping around 32% on Tuesday. Calidi Biotherapeutics recently announced collaboration with SIGA Technologies to advance Calidi&#8217;s RTNova virotherapy for lung cancer and metastatic solid tumors.</li>
<li>ReTo Eco-Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RETO#NASDAQ">RETO</a>) declined 12.4% to $2.19.</li>
<li>PetMed Express, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) shares fell 12.1% to $4.1350 following mixed fourth-quarter results. The company said results were negatively impacted by a challenging macro environment and industry dynamics.</li>
<li>SmartKem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>) declined 11.7% to $6.10.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) dipped 9.9% to $0.4036.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) fell 8.2% to $15.84</li>
<li>Oblong, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) fell 8.1% to $0.1847 after declining 5% on Tuesday. Obglong recently signed a non-binding letter of intent to acquire Dwellwell Analytics.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/top-stories/24/06/39290971/jim-cramer-likes-this-energy-stock-with-4-yield-recommends-buying-draftkings">Jim Cramer Likes This Energy Stock With 4% Yield, Recommends Buying DraftKings</a>

Intraday Update

Markets

Trading Ideas

AAPL

AFRM

AVGR

CASY

CLDI

DRCT

ENVX

FEBO

GDHG

GOOG

GOOGL

KITT

MDIA

MREO

NOVA

OBLG

ORCL

PETS

RDFN

RETO

SIFY

SMTK

TCON

THMO

TNXP

UPST

WLGS

WULF

Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. </li>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 20.94% to $1.42. The market value of their outstanding shares is at $26.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares fell 31.4% to $0.38 during Wednesday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares decreased by 25.92% to $0.8. The company's market cap stands at $2.1 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares declined by 21.86% to $0.5. The market value of their outstanding shares is at $31.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock fell 21.76% to $2.59. The market value of their outstanding shares is at $30.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 16.67% to $0.23. The market value of their outstanding shares is at $14.4 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 16.16% to $1.61. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

CYCN

LGVN

NNVC

VTVT

Streamline Health Solutions shares are trading lower after the company reported worse-than-expected Q1 EPS results.

<h3>Gainers</h3>
<ul>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million. </li>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million. </li>
<li>Oramed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORMP#NASDAQ">ORMP</a>) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock rose 12.72% to $3.1. The market value of their outstanding shares is at $3.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares decreased by 40.5% to $0.33 during Wednesday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 11.86% to $0.24. The market value of their outstanding shares is at $15.2 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares decreased by 10.94% to $0.57. The market value of their outstanding shares is at $35.4 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares decreased by 8.28% to $0.8. The company's market cap stands at $132.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 8.11% to $1.7. The market value of their outstanding shares is at $2.4 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) stock fell 7.91% to $0.28. The market value of their outstanding shares is at $53.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

CYCC

MOLN

ORMP

TVGN

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Due to the continued unpredictability of timing related to the closing of new contracts, the Company has not provided more specific&nbsp;guidance&nbsp;related to the timing of bookings.

Streamline Health Reiterates $15.5M Implemented SaaS ARR Adjusted EBITDA Breakeven Run Rate Expectation; Expects To Achieve This Run Rate During H2 Of FY24

Streamline Health jumps 12%, enters contract for 750-bed center in Texas

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Streamline Health Solutions (STRM – Research Report). The comp...

Streamline Health Solutions (STRM) Gets a Buy from Craig-Hallum

Craig-Hallum Remains a Buy on Streamline Health Solutions (STRM)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Streamline Health Solutions (STRM – Research Report) today. The company's shares closed...

Craig-Hallum Keeps Their Buy Rating on Streamline Health Solutions (STRM)

Streamline Health GAAP EPS of -$0.05 misses by $0.01, revenue of $4.48M beats by $0.15M

Streamline Health Solutions, Inc. (STRM) Q2 2024 Earnings Call Transcript

Streamline Health announces 1-for-15 reverse stock split

An update from Streamline Health Solutions ( ($STRM) ) is now available. Streamline Health Solutions, Inc. has announced a 1-for-15 reverse stock s...

Streamline Health Announces Reverse Split, Adjusts Securities

These are the upcoming stock splits for the week of September 30 to October 4, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a co...

Upcoming Stock Splits This Week (September 30 to October 4) – Stay Invested

Streamline Health (STRM) Solutions has expanded its relationship with an existing eValuator client include the recently released eValuator Quality ...

Streamline Health expands relationship with existing eValuator client

LRCX

RYAAY

SMCI

Press Releases

Streamline Health® Reports Fiscal First Quarter 2024 Financial Results

Streamline Health® Announces New eValuator™ Contract with 750-Bed Academic Medical Center

Streamline Health® Expands RevID™ Agreement With 400-Bed Children's Health System

Streamline Health® To Report Fiscal Second Quarter 2024 Financial Performance

Streamline Health® Reports Fiscal Second Quarter 2024 Financial Results

Streamline Health® Announces 1-For-15 Reverse Stock Split

Streamline Health® Debuts eValuator™ Quality Module

Streamline Health® Adds Quality Module to Existing eValuator Relationship

Streamline Health® Adds Quality Module to Third eValuator™ Client

Streamline Health® Announces New eValuator™ Contract With Texas-Based Health System

Comments

Streamline Health Solns

Vendite allo scoperto

Streamline Health Solns (NASDAQ:STRM) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO